During the past decade, Marin Endocrine Care & Research, Inc. conducted 16 clinical trials. In the 10-year time frame, 16 clinical trials started and 20 clinical trials were completed, i.e. on average, 125% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 9 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Marin Endocrine Care & Research, Inc." #1 sponsor was "Eli Lilly and Company" with 6 trials, followed by "AstraZeneca" with 5 trials sponsored, "Radius Health, Inc." with 2 trials sponsored, "Bayer" with 1 trials sponsored and "Boehringer Ingelheim" with 1 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Marin Endocrine Care & Research, Inc." #1 collaborator was "Bristol-Myers Squibb" with 3 trials as a collaborator, "Astra Zeneca, Bristol-Myers Squibb" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator, "Jaeb Center for Health Research" with 1 trials as a collaborator and "Medpace, Inc." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Marin Endocrine Care & Research, Inc." are "Type 2 Diabetes" (6 trials), "Diabetes Mellitus, Type 2" (4 trials), "Type 2 Diabetes Mellitus" (3 trials), "Diabetes Mellitus, Type 1" (2 trials) and "Type 1 Diabetes Mellitus" (2 trials). Many other conditions were trialed in "Marin Endocrine Care & Research, Inc." in a lesser frequency.

Most popular intervention types in "Marin Endocrine Care & Research, Inc." are "Drug" (21 trials), "Biological" (2 trials), "Device" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Dapagliflozin" (4 trials), "Dulaglutide" (2 trials), "Insulin Degludec" (2 trials) and "Insulin Glargine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Marin Endocrine Care & Research, Inc." are 23 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Marin Endocrine Care & Research, Inc.". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in Marin Endocrine Care & Research, Inc., undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Marin Endocrine Care & Research, Inc., 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".